Sepsis, the most common cause of admission to an intensive care unit (ICU), has had an increased incidence and prevalence over the last years with a simultaneous decrease in its short-term mortality. Sepsis survivors are more frequently discharged from hospital and often experience long-term outcomes such as late mortality, immune dysfunction, secondary infections, impaired quality of life, and unplanned readmissions. Early recognition and management of sepsis have challenged emergency care and critical care physicians and nurses. New sepsis definitions were produced and the Surviving Sepsis Campaign (SSC) 2016 was updated recently. Although hospital readmissions after sepsis are common, associated risk factors and how to manage patients who survive an episode of sepsis still need clarification. The immune dysfunction caused by sepsis/septic shock is complex, persistent, affects inflammatory and anti-inflammatory systems, and might be associated with long-term outcomes of sepsis. Several randomized controlled trials (RCT) that analyzed new (and old) interventions in sepsis/septic shock are discussed in this review in parallel with the SSC 2016 recommendations and other guidelines when relevant. RCTs addressing incidence, treatment, and prevention of important sepsis-associated organ dysfunction such as the acute respiratory distress syndrome, acute kidney injury, and brain dysfunction are highlighted. Finally, we briefly discuss the need for novel targets, predictive biomarkers, and new designs of RCTs in sepsis.

Journal Section:
Editor's choice
Keywords:
Sepsis, Septic shock, Early treatment, Albumin, Transfusion, Renal therapy
1.
Hall MJ, Williams SN, DeFrances CJ, Golosinskiy A: Inpatient care for septicemia or sepsis: a challenge for patients and hospitals. NCHS Data Brief 2011;62:1-8.
2.
Hoyert DL, Xu J: Deaths: preliminary data for 2011. Natl Vital Stat Rep 2012;61:1-51.
3.
Navaneelan T, Alam S, Peters PA, Phillips O: Deaths involving sepsis in Canada. Health at a Glance. 2016, http://www.statcan.gc.ca/pub/82-624-x/2016001/article/14308-eng.htm.
4.
Perner A, Gordon AC, De Backer D, et al: Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Med 2016;42:1958-1969.
5.
Chang DW, Tseng CH, Shapiro MF: Rehospitalizations following sepsis: common and costly. Crit Care Med 2015;43:2085-2093.
6.
Donnelly JP, Hohmann SF, Wang HE: Unplanned readmissions after hospitalization for severe sepsis at academic medical center-affiliated hospitals. Crit Care Med 2015;43:1916-1927.
7.
Goodwin AJ, Rice DA, Simpson KN, Ford DW: Frequency, cost, and risk factors of readmissions among severe sepsis survivors. Crit Care Med 2015;43:738-746.
8.
Jones TK, Fuchs BD, Small DS, et al: Post-acute care use and hospital readmission after sepsis. Ann Am Thorac Soc 2015;12:904-913.
9.
Liu V, Lei X, Prescott HC, et al: Hospital readmission and healthcare utilization following sepsis in community settings. J Hosp Med 2014;9:502-507.
10.
Mayr FB, Talisa VB, Balakumar V, et al: Proportion and cost of unplanned 30-day readmissions after sepsis compared with other medical conditions. JAMA 2017;317:530-531.
11.
Ortego A, Gaieski DF, Fuchs BD, et al: Hospital-based acute care use in survivors of septic shock. Crit Care Med 2015;43:729-737.
12.
Prescott HC, Langa KM, Liu V, Escobar GJ, Iwashyna TJ: Increased 1-year healthcare use in survivors of severe sepsis. Am J Respir Crit Care Med 2014;190:62-69.
13.
Kissoon N, Daniels R, van der Poll T, Finfer S, Reinhart K: Sepsis - the final common pathway to death from multiple organ failure in infection. Crit Care Med 2016;44:e446.
14.
Wang H, Naghavi M, Allen C: Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1459-1544.
15.
Fleischmann C, Scherag A, Adhikari NK, et al: Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016;193:259-272.
16.
Rhee C, Gohil S, Klompas M: Regulatory mandates for sepsis care - reasons for caution. N Engl J Med 2014;370:1673-1676.
17.
Rhodes A, Evans LE, Alhazzani W, et al: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017;45:486-552.
18.
Gaieski DF, Edwards JM, Kallan MJ, Carr BG: Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 2013;41:1167-1174.
19.
Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R: Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308-1316.
20.
Marik PE, Linde-Zwirble WT, Bittner EA, Sahatjian J, Hansell D: Fluid administration in severe sepsis and septic shock, patterns and outcomes: an analysis of a large national database. Intensive Care Med 2017;43:625-632.
21.
Iwashyna TJ, Ely EW, Smith DM, Langa KM: Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010;304:1787-1794.
22.
Jackson JC, Pandharipande PP, Girard TD, et al: Depression, post-traumatic stress disorder, and functional disability in survivors of critical illness in the BRAIN-ICU study: a longitudinal cohort study. Lancet Respir Med 2014;2:369-379.
23.
Winters BD, Eberlein M, Leung J, et al: Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 2010;38:1276-1283.
24.
Sun A, Netzer G, Small DS, et al: Association between index hospitalization and hospital readmission in sepsis survivors. Crit Care Med 2016;44:478-487.
25.
Linder A, Fjell C, Levin A, et al: Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med 2014;189:1075-1081.
26.
Schmidt K, Worrack S, Von Korff M, et al: Effect of a primary care management intervention on mental health-related quality of life among survivors of sepsis: a randomized clinical trial. JAMA 2016;315:2703-2711.
27.
Goddard SL, Adhikari NK: The challenging task of improving the recovery of ICU survivors. JAMA 2016;315:2671-2672.
28.
Yende S, D'Angelo G, Kellum JA, et al: Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008;177:1242-1247.
29.
Delano MJ, Ward PA: The immune system's role in sepsis progression, resolution, and long-term outcome. Immunol Rev 2016;274:330-353.
30.
Hotchkiss RS, Monneret G, Payen D: Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862-874.
31.
van Vught LA, Klein Klouwenberg PM, Spitoni C, et al: Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 2016;315:1469-1479.
32.
Singer M, Deutschman CS, Seymour CW, et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801-810.
33.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
34.
Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256.
35.
Seymour CW, Liu VX, Iwashyna TJ, et al: Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:762-774.
36.
Shankar-Hari M, Phillips GS, Levy ML, et al: Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:775-787.
37.
Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al: Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med 2016;42:1535-1545.
38.
Chytra I, Stepan M, Benes J, et al: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012;16:R113.
39.
Dulhunty JM, Roberts JA, Davis JS, et al: A multicenter randomized trial of continuous versus intermittent β-lactam infusion in severe sepsis. Am J Respir Crit Care Med 2015;192:1298-1305.
40.
de Jong E, van Oers JA, Beishuizen A, et al: Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016;16:819-827.
41.
Timsit JF, Azoulay E, Schwebel C, et al: Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial. JAMA 2016;316:1555-1564.
42.
Pappas PG, Kauffman CA, Andes DR, et al: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1-e50.
43.
Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377.
44.
ARISE Investigators; ANZICS Clinical Trials Group, Peake SL, et al: Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014;371:1496-1506.
45.
Mouncey PR, Osborn TM, Power GS, et al: Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015;372:1301-1311.
46.
Pro CI, Yealy DM, Kellum JA, et al: A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014;370:1683-1693.
47.
Hjortrup PB, Haase N, Bundgaard H, et al: Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial. Intensive Care Med 2016;42:1695-1705.
48.
Silversides JA, Major E, Ferguson AJ, et al: Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med 2017;43:155-170.
49.
Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA: Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011;39:259-265.
50.
Liu KD, Thompson BT, Ancukiewicz M, et al: Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. Crit Care Med 2011;39:2665-2671.
51.
Gamper G, Havel C, Arrich J, et al: Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2016;2:CD003709.
52.
Avni T, Lador A, Lev S, et al: Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One 2015;10:e0129305.
53.
De Backer D, Aldecoa C, Njimi H, Vincent JL: Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis*. Crit Care Med 2012;40:725-730.
54.
Sakr Y, Reinhart K, Vincent JL, et al: Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 2006;34:589-597.
55.
Zhou F, Mao Z, Zeng X, et al: Vasopressors in septic shock: a systematic review and network meta-analysis. Ther Clin Risk Manag 2015;11:1047-1059.
56.
De Backer D, Biston P, Devriendt J, et al: Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779-789.
57.
Caironi P, Tognoni G, Masson S, et al: Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014;370:1412-1421.
58.
Charpentier J, Mira JP: Efficacy and tolerance of hyperoncotic albumin administration in septic shock patients: the EARSS study. Intensive Care Med 2011;37(suppl 2):S115.
59.
Keh D, Trips E, Marx G, et al: Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA 2016;316:1775-1785.
60.
Nguyen DN, Huyghens L, Zhang H, et al: Cortisol is an associated-risk factor of brain dysfunction in patients with severe sepsis and septic shock. BioMed Res Int 2014;2014:712742.
61.
Schreiber MP, Colantuoni E, Bienvenu OJ, et al: Corticosteroids and transition to delirium in patients with acute lung injury. Crit Care Med 2014;42:1480-1486.
62.
Bellani G, Laffey JG, Pham T, et al: Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016;315:788-800.
63.
Alhazzani W, Truwit J: Statins in patients with sepsis and ARDS: is it over? Yes. Intensive Care Med 2017;43:672-674.
64.
Pasin L, Landoni G, Castro ML, et al: The effect of statins on mortality in septic patients: a meta-analysis of randomized controlled trials. PLoS One 2013;8:e82775.
65.
Morandi A, Hughes CG, Thompson JL, et al: Statins and delirium during critical illness: a multicenter, prospective cohort study. Crit Care Med 2014;42:1899-1909.
66.
McAuley DF, Laffey JG, O'Kane CM, et al: Simvastatin in the acute respiratory distress syndrome. N Engl J Med 2014;371:1695-1703.
67.
National Heart, Lung, and Blood Institute ARDS Clinical Trials Network,, Truwit JD, Bernard GR, et al: Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014;370:2191-2200.
68.
Kruger PS, Terblanche M: Statins in patients with sepsis and ARDS: is it over? No. Intensive Care Med 2017;43:675-676.
69.
Calfee CS, Delucchi K, Parsons PE, et al: Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014;2:611-620.
70.
Morel J, Singer M: Statins, fibrates, thiazolidinediones and resveratrol as adjunctive therapies in sepsis: could mitochondria be a common target? Intensive Care Med Exp 2014;2:9.
71.
McAuley D, Charles PE, Papazian L: Statins in patients with sepsis and ARDS: is it over? We are not sure. Intensive Care Med 2017;43:677-679.
72.
Hernandez G, Vaquero C, Gonzalez P, et al: Effect of postextubation high-flow nasal cannula vs conventional oxygen therapy on reintubation in low-risk patients: a randomized clinical trial. JAMA 2016;315:1354-1361.
73.
Hernandez G, Vaquero C, Colinas L, et al: Effect of postextubation high-flow nasal cannula vs noninvasive ventilation on reintubation and postextubation respiratory failure in high-risk patients: a randomized clinical trial. JAMA 2016;316:1565-1574.
74.
Patel BK, Wolfe KS, Pohlman AS, Hall JB, Kress JP: Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 2016;315:2435-2441.
75.
Girardis M, Busani S, Damiani E, et al: Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the Oxygen-ICU Randomized Clinical Trial. JAMA 2016;316:1583-1589.
76.
Gordon AC, Perkins GD, Singer M, et al: Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 2016;375:1638-1648.
77.
Gaudry S, Hajage D, Schortgen F, et al: Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med 2016;375:122-133.
78.
Zarbock A, Kellum JA, Schmidt C, et al: Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN Randomized Clinical Trial. JAMA 2016;315:2190-2199.
79.
Gordon AC, Mason AJ, Thirunavukkarasu N, et al: Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH Randomized Clinical Trial. JAMA 2016;316:509-518.
80.
Russell JA, Walley KR, Singer J, et al: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-887.
81.
Russell JA, Walley KR, Gordon AC, et al: Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009;37:811-818.
82.
Gordon AC, Mason AJ, Perkins GD, et al: The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med 2014;42:1325-1333.
83.
Torgersen C, Dunser MW, Wenzel V, et al: Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 2010;36:57-65.
84.
Kellum JA, Chawla LS, Keener C, et al: The effects of alternative resuscitation strategies on acute kidney injury in patients with septic shock. Am J Respir Crit Care Med 2016;193:281-287.
85.
Ely EW, Girard TD, Shintani AK, et al: Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in critically ill patients. Crit Care Med 2007;35:112-117.
86.
Ely EW, Shintani A, Truman B, et al: Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004;291:1753-1762.
87.
Pandharipande PP, Girard TD, Jackson JC, et al: Long-term cognitive impairment after critical illness. N Engl J Med 2013;369:1306-1316.
88.
Simons KS, Laheij RJ, van den Boogaard M, et al: Dynamic light application therapy to reduce the incidence and duration of delirium in intensive-care patients: a randomised controlled trial. Lancet Respir Med 2016;4:194-202.
89.
Needham DM, Colantuoni E, Dinglas VD, et al: Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: an ancillary study to a randomised controlled trial. Lancet Respir Med 2016;4:203-212.
90.
Reade MC, Eastwood GM, Bellomo R, et al: Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: a randomized clinical trial. JAMA 2016;315:1460-1468.
91.
Barr J, Fraser GL, Puntillo K, et al: Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013;41:263-306.
92.
Padhi S, Kemmis-Betty S, Rajesh S, et al: Blood transfusion: summary of NICE guidance. BMJ 2015;351:h5832.
93.
Carson JL, Guyatt G, Heddle NM, et al: Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 2016;316:2025-2035.
94.
Holst LB, Haase N, Wetterslev J, et al: Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014;371:1381-1391.
95.
Dupuis C, Sonneville R, Adrie C, et al: Impact of transfusion on patients with sepsis admitted in intensive care unit: a systematic review and meta-analysis. Ann Intensive Care 2017;7:5.
96.
Lacroix J, Hebert PC, Fergusson DA, et al: Age of transfused blood in critically ill adults. N Engl J Med 2015;372:1410-1418.
97.
Harvey SE, Parrott F, Harrison DA, et al: Trial of the route of early nutritional support in critically ill adults. N Engl J Med 2014;371:1673-1684.
98.
Harvey SE, Parrott F, Harrison DA, et al: A multicentre, randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route in critically ill patients (CALORIES). Health Technol Assess 2016;20:1-144.
99.
Meisel C, Schefold JC, Pschowski R, et al: Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640-648.
100.
Chang KC, Burnham CA, Compton SM, et al: Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care 2013;17:R85.
101.
Topchiy E, Cirstea M, Kong HJ, et al: Lipopolysaccharide is cleared from the circulation by hepatocytes via the low density lipoprotein receptor. PLoS One 2016;11: e0155030.
102.
Walley KR, Francis GA, Opal SM, et al: The central role of proprotein convertase subtilisin/kexin type 9 in septic pathogen lipid transport and clearance. Am J Respir Crit Care Med 2015;192:1275-1286.
103.
Boyd JH, Fjell CD, Russell JA, et al: Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis. J Innate Immun 2016;8:211-220.
104.
Walley KR, Thain KR, Russell JA, et al: PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med 2014;6:258ra143.
105.
Howell MD, Davis AM: Management of sepsis and septic shock. JAMA 2017;317:847-848.
106.
Matthay MA, Liu KD: New strategies for effective therapeutics in critically ill patients. JAMA 2016;315:747-748.
107.
Ramanan M, Myburgh J, Finfer S, Bellomo R, Venkatesh B: Publication of secondary analyses from randomized trials in critical care. N Engl J Med 2016;375:2105-2106.
108.
Abraham E: New definitions for sepsis and septic shock: continuing evolution but with much still to be done. JAMA 2016;315:757-759.
109.
Sprung CL, Schein RM, Balk RA: The new sepsis consensus definitions: the good, the bad and the ugly. Intensive Care Med 2016;42:2024-2026.
110.
Russell JA, Lee T, Singer J, et al: The Septic Shock 3.0 Definition and Trials: a vasopressin and septic shock trial experience. Crit Care Med 2017.
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.